Curis Announces Agreement to Develop CUDC-907; Watson Launches Generic LIPITOR® Print E-mail
By Staff and Wire Reports   
Wednesday, 30 November 2011 17:42
Below is a look at some of the headlines for companies that made news in the healthcare sector on November 30, 2011.

Curis, Inc. (NASDAQ:CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, announced the Company has entered into an agreement under which The Leukemia & Lymphoma Society (LLS) will support Curiss ongoing development of its oral small molecule dual Pi3K and HDAC inhibitor CUDC-907, for patients with B-cell lymphoma and multiple myeloma.

We are delighted to collaborate with LLS to further develop CUDC-907. Our preclinical evidence suggests that its dual synergistic inhibition of PI3K and HDAC acts by disrupting cancer pathway networks that are important to the emergence and growth of B-cell lymphoma and multiple myeloma, said Dan Passeri, Curiss President and Chief Executive Officer. LLSs capital commitment to this program, along with their extensive knowledge of hematological malignancies, will be important resources as we seek to advance this promising first-in-class molecule.

This agreement was entered into as part of LLSs Therapy Acceleration Program (TAP), a strategic initiative to speed the development of therapies that have the potential to change the standard of care for patients with blood cancers, especially in areas of high unmet medical need.

Under the agreement, LLS will fund approximately 50% of the direct costs of the development of CUDC-907, up to $4 million. Curis is currently conducting preclinical studies of CUDC-907 required to file an investigational new drug application (IND) seeking to advance the molecule into a Phase Ia dose escalation clinical trial in B-cell lymphoma and multiple myeloma. Curis expects to file the IND and start patient enrollment in the second half of 2012. If this study is successful, LLS has also agreed to support Curiss subsequent Phase Ib or Phase IIa study in one or more specific indications as well as Curis ongoing investigation of biomarkers for CUDC-907 in these diseases.

Curis will be obligated to continue development of CUDC-907 following the term of this agreement, provided that study results are positive and that there is a regulatory path forward and would be required to make a payment to LLS if it did not continue development in this success scenario. In the event that future studies of CUDC-907 are unsuccessful, the funding received from LLS would be treated as a non-refundable grant to Curis. Assuming that Curis licenses or partners CUDC-907 in B-cell lymphoma or multiple myeloma, or, in the event that Curis commercializes the drug candidate itself in these indications, Curis would be obligated to pay LLS future milestones of up to 2.5 times the funding amounts received from LLS under the agreement, primarily upon meeting defined regulatory submission, approval and commercialization objectives.


Watson Pharmaceuticals, Inc. (NYSE:WPI)
confirmed Watson Pharmaceuticals, Inc., has launched an authorized generic version of LIPITOR®(atorvastatin calcium tablets) as part of an exclusive agreement with Pfizer Inc.  Watson began shipping the product today.  LIPITOR®is indicated as an adjunct to diet to reduce elevated total cholesterol, LDL, triglycerides and to increase HDL cholesterol.

Under the terms of the exclusive supply and distribution agreement, Pfizer manufactures and supplies Watson with all dosage strengths of the authorized generic product. Watson markets and distributes the product in the United States. Pfizer will receive a share of the net sales from Watson's sales of the product. The agreement runs until November 30, 2016. Other terms of the agreement have not been disclosed.

For the most recent twelve months ending September 30, 2011, LIPITOR®had sales of approximately $7.8 billion, according to IMS Health (RX) data.

Also Wednesday:

Stratos Product Development LLC today announced its President, Sean MacLeod, and AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) Chief Executive Officer, Richard King, will present at the BIOMEDevice conference in San Jose on Stratos' continued collaboration with AcelRx to support software and electrical design of AcelRx's lead product candidate, ARX-01.

Advanced Cell Technology, Inc. ("ACT"; OTCBB: ACTC)
, a leader in the field of regenerative medicine, announced today that the company’s director of business development, Matthew Vincent, Ph.D., will be presenting at the 2011 Stem Cell Meeting on the Mesa’s Investor and Partnering Forum, Nov. 30 to Dec. 1 in La Jolla, California.

Affymetrix, Inc., (NASDAQ:AFFX)
today announced that it has signed a definitive agreement to acquire eBioscience, Inc., a privately-held San Diego, CA-based company with an industry-leading position in flow cytometry and immunoassay reagents for immunology and oncology research and diagnostics.

Anika Therapeutics, Inc. (Nasdaq: ANIK)
a leader in products for tissue protection, healing and repair, based on hyaluronic acid (“HA”) technology, today announced that Chief Operating Officer Frank Luppino will present at the LD Micro Conference in Los Angeles.

Astex Pharmaceuticals, Inc. (NASDAQ: ASTX)
, a pharmaceutical company dedicated to the discovery and development of novel therapeutics, today announced that Tom Heightman, Ph.D., director, medicinal chemistry, will co-chair and present at the 2nd World Epigenetics Summit: Unlocking the Commercial and Therapeutic Potential of Epigenetics Research on December 6 to 8, 2011 in Munich.

BioClinica®, Inc. (NASDAQ: BIOC)
, a global provider of clinical trial management solutions, today announced that Onconova Therapeutics®, Inc. has extended agreements using BioClinica Express electronic data capture (EDC) and data management services to support their clinical trials world-wide.

Boston Scientific Corporation (NYSE: BSX)
announced that, along with today's introduction of a new family of INCEPTA™ and ENERGEN™ implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy defibrillators (CRT-Ds), it is providing an extended warranty for these devices in the U.S. and many international countries of up to 10 years, depending on model.

Cannabis Science, Inc. (OTCBB: CBIS)
, a pioneering US biotech company developing pharmaceutical cannabis products, is pleased to announce that the first two Cannabis Science Brand Formulations, Cannabis Science CT-1 and Cannabis Science MT-1 are now available at both Cannabis Therapeutics and Marisol Therapeutics exclusively for Colorado State licensed medical marijuana patients.

Speaking today at the plenary session of the 7th Annual European Antibody Congress in Geneva, Dr. Anat Cohen-Dayag, President and CEO of Compugen Ltd. (NASDAQ: CGEN), presented Compugen’s Antibody Target Discovery Platform, one of the Company's predictive discovery platforms for novel therapeutic targets.

Curis, Inc. (NASDAQ: CRIS)
, a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that the Company has entered into an agreement under which The Leukemia & Lymphoma Society (LLS) will support Curis’s ongoing development of its oral small molecule dual Pi3K and HDAC inhibitor CUDC-907, for patients with B-cell lymphoma and multiple myeloma.

iBio, Inc. (NYSE AMEX: IBIO)
today announced that it has submitted its plan (the "Plan") to satisfy the requirements for continued listing on the NYSE Amex LLC (the "Exchange") to the Exchange's Corporate Compliance Department management (the "Staff") for their review, and that the Company is currently awaiting a response from the Staff in connection therewith.

FONAR Corporation (NASDAQ: FONR)
, The Inventor of MR Scanning™, reported the sale today of its UPRIGHT® Multi-Position™ MRI to a radiology practice in western USA.

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced the company will present results from studies of its investigational medicine pertuzumab in HER2-positive breast cancer at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium December 6-10.

Given Imaging Ltd. (NASDAQ: GIVN), a world leader in specialty GI products and pioneer of capsule endoscopy, today announced that it has filed a patent infringement lawsuit against Intromedic Co. Ltd., in Seoul's Central District Court.

Nutra Pharma Corporation (OTCBB: NPHC)
, a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that the journal Neuropharmacology will be publishing a mechanism study on the use of Alpha-Cobratoxin, a component of cobra venom, as a treatment for pain.

Omeros Corporation (NASDAQ: OMER)
today reported that with its identification of compounds that interact selectively with each of four additional orphan G protein-coupled receptors (GPCRs) – GPR19, GPR20, GPR31 and GPR141 – it has now unlocked over 20 percent of the 77 Class A orphans.

Palatin Technologies, Inc. (NYSE Amex: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced that Dr. Carl Spana, President and Chief Executive Officer, will be presenting at Windhover's Therapeutic Area Partnerships conference on Thursday, December 1, 2011.

Unigene Laboratories, Inc. (OTCBB: UGNE), a leader in the design, delivery, manufacture and development of peptide-based therapeutics, today announced that Cara Therapeutics commenced the Phase 1 study of its oral proprietary peptide-based, investigational drug, CR845, a novel peripherally-acting kappa opioid agonist in healthy volunteers.

"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit!! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus